Takara Bio expands gene therapy pipeline
HONG KONG – With a supportive environment for regenerative medicine created by the Japanese government, Takara Bio Inc. (TYO: 4974), has launched a phase I clinical trial to study its MAGE-A4 antigen-specific T-cell receptor (TCR) gene therapy in esophageal cancer.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter